TLDR: Monte Rosa Therapeutics has presented preclinical data at ACR Convergence 2025 on their novel molecular glue degrader, MRT-6160, for treating autoimmune and inflammatory diseases. Their discovery engine, QuEEN™, leverages AI-guided chemistry to design highly selective degraders, marking a significant advancement in personalized medicine for complex conditions like lupus, Sjögren’s disease, and rheumatoid arthritis.
BOSTON, October 24, 2025 – Monte Rosa Therapeutics, a clinical-stage biotechnology firm, announced groundbreaking preclinical data at the ACR Convergence 2025 conference in Chicago, IL. The presentation highlighted the therapeutic potential of MRT-6160, a VAV1-directed molecular glue degrader (MGD), in treating a range of immune-mediated diseases, including systemic lupus erythematosus (SLE), Sjögren’s disease, and rheumatoid arthritis (RA).
The company’s proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is at the forefront of this innovation. This platform uniquely combines AI-guided chemistry with diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. MGDs represent a new class of small molecule protein degraders capable of targeting diseases previously considered ‘undruggable’ by other therapeutic modalities.
This development underscores a broader trend in healthcare where artificial intelligence is increasingly being explored for its transformative applications in autoimmune diseases. AI’s ability to analyze vast amounts of patient data can enable earlier diagnosis by detecting subtle differences in patient information, potentially even before the onset of symptoms. For instance, AI has been studied for early diagnosis of multiple sclerosis (MS) and SLE.
Beyond early detection, AI is proving instrumental in predicting disease risk by identifying factors in individuals before symptoms manifest, and in improving diagnostic accuracy by distinguishing specific autoimmune conditions from others. Machine learning models, a subset of AI, have already been used to differentiate celiac disease from irritable bowel syndrome.
Furthermore, AI’s application extends to six main areas in autoimmune disease management: patient identification, risk factors and prognosis assessment, diagnosis, classification of disease subtypes, monitoring and decision support, and drug discovery. In drug discovery, AI accelerates and enhances the development process through virtual screening, prediction of molecular-drug interactions, and optimization of drug design.
Also Read:
- Expedition Medicines Launched by Flagship Pioneering with $50M to Revolutionize Small Molecule Drug Discovery Using Generative AI
- Acrivon Therapeutics Showcases Generative AI KaiSR Model and Promising ACR-2316 Preclinical Data at AACR-NCI-EORTC Conference
While the integration of AI into autoimmune disease research and patient care holds immense promise for delivering optimal and personalized treatment, it also presents challenges related to data integration, computational power, and the need for robust model validation. Nevertheless, the advancements showcased by Monte Rosa Therapeutics at ACR Convergence 2025, powered by AI-guided chemistry, signal a new era in the fight against complex autoimmune conditions.
